Piper Sandler Maintains Overweight on Acceleron Pharma, Raises Price Target to $135

Piper Sandler analyst Danielle Brill maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $73 to $135.

Benzinga · 01/28/2020 13:32

Piper Sandler analyst Danielle Brill maintains Acceleron Pharma (NASDAQ:XLRN) with a Overweight and raises the price target from $73 to $135.